Blockchain Registration Transaction Record

SeaStar Medical's QUELIMMUNE Wins NKF's 2025 Corporate Innovator Award

SeaStar Medical's QUELIMMUNE device awarded by NKF for treating pediatric AKI, showcasing a 77% mortality reduction and no dialysis dependency after 60 days.

The recognition of SeaStar Medical's QUELIMMUNE device by the National Kidney Foundation underscores a significant advancement in treating pediatric acute kidney injury, a condition with high mortality rates. This development is crucial for families and healthcare providers, offering hope for reducing deaths and long-term complications in affected children. Moreover, the ongoing expansion of QUELIMMUNE's application to adult AKI patients could revolutionize kidney disease treatment, addressing a widespread but often undiagnosed condition affecting millions.